Autosomal dominant myosin storage myopathy
aw-toh-soh-muhl doh-mi-nuhnt my-oh-sin stor-ij my-oh-puh-thee
Also known as: Myosin storage myopathy, MYH7-related myopathy
At a Glance
What is Autosomal dominant myosin storage myopathy?
Autosomal dominant myosin storage myopathy is a rare genetic disorder that affects the muscles. It is caused by mutations in the MYH7 gene, which is responsible for producing a protein called myosin. Myosin is crucial for muscle contraction, and when it is abnormal, it leads to muscle weakness. The condition primarily affects skeletal muscles, but it can also involve the heart, leading to cardiomyopathy. Early symptoms often include muscle weakness and fatigue, while later symptoms can involve more severe muscle wasting and heart problems. Early diagnosis is important to manage symptoms and prevent complications. The condition can have a significant impact on family life, as it may require ongoing medical care and lifestyle adjustments. Prognosis varies; some individuals maintain a good quality of life with treatment, while others may experience progressive muscle weakness. Daily life for affected individuals may involve physical therapy and regular monitoring by healthcare providers. Supportive therapies can help maintain mobility and function. Genetic counseling is recommended for families, as the condition is inherited. Understanding and managing the condition can improve outcomes and quality of life for those affected.
Medical Definition
Autosomal dominant myosin storage myopathy is a genetic disorder characterized by the accumulation of myosin in muscle fibers. Pathologically, it involves the presence of subsarcolemmal hyaline bodies in muscle tissue. Histologically, muscle biopsies reveal the presence of these hyaline bodies, which are diagnostic of the condition. It is classified under myopathies related to defects in the sarcomeric proteins. Epidemiologically, it is an extremely rare condition with a prevalence of approximately 1 in 1,000,000. The disease course can vary, with some individuals experiencing stable symptoms and others progressing to more severe muscle weakness and cardiomyopathy over time.
Autosomal dominant myosin storage myopathy Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Muscle weakness typically manifests as difficulty in performing everyday tasks such as climbing stairs or lifting objects. It is caused by the accumulation of abnormal myosin protein in muscle fibers, which disrupts normal muscle contraction. Over time, muscle weakness can progress to affect larger muscle groups, leading to significant mobility issues. Patients often require physical therapy to maintain muscle function and may need assistive devices for mobility.
Fatigue presents as a persistent feeling of tiredness and lack of energy, even after adequate rest. This symptom is due to the increased energy expenditure needed to compensate for weakened muscles. As the condition progresses, fatigue can become more pronounced, affecting the patient's ability to perform daily activities. Management includes energy conservation techniques and possibly medication to improve endurance.
Muscle cramps are sudden, involuntary contractions of muscles that can cause significant discomfort. They occur because of the altered muscle fiber composition and impaired calcium handling within the muscle cells. Over time, cramps can become more frequent and severe, particularly during physical activity. Stretching exercises and hydration are commonly recommended to alleviate cramps.
Common
Cardiomyopathy is a disease of the heart muscle that can lead to heart failure. It is caused by the same genetic mutation affecting the myosin protein in skeletal muscles, which also impacts cardiac muscle function. As the disease progresses, patients may experience symptoms such as shortness of breath and chest pain. Regular cardiac monitoring and medication are essential to manage this condition.
Joint contractures involve the permanent tightening of muscles, tendons, and skin that restricts movement. This occurs due to prolonged muscle weakness and imbalance, leading to changes in joint structure. Over time, contractures can severely limit mobility and daily functioning. Physical therapy and, in some cases, surgical intervention may be necessary to improve joint flexibility.
Respiratory difficulties manifest as shortness of breath and reduced lung capacity. These issues arise from weakness in the respiratory muscles, including the diaphragm. As the condition advances, patients may require respiratory support, such as non-invasive ventilation. Breathing exercises and respiratory therapy can help maintain lung function.
Less Common
Scoliosis is a lateral curvature of the spine that can develop due to muscle weakness and imbalance. It results from the uneven pull on the spine by weakened muscles, leading to a curved posture. Over time, scoliosis can cause back pain and impact respiratory function. Treatment may involve bracing or surgery, depending on the severity of the curvature.
Swallowing difficulties, or dysphagia, occur when weakened muscles affect the ability to swallow effectively. This is due to the involvement of muscles in the throat and esophagus, which can be compromised by the disease. As dysphagia progresses, it can lead to nutritional deficiencies and increased risk of aspiration. Speech therapy and dietary modifications are often recommended to manage this symptom.
What Causes Autosomal dominant myosin storage myopathy?
Autosomal dominant myosin storage myopathy is primarily caused by mutations in the MYH7 gene, located on chromosome 14q11.2. The MYH7 gene encodes the beta-myosin heavy chain, a crucial component of the sarcomere in cardiac and skeletal muscle fibers. Mutations in MYH7 often result in missense changes that alter the protein's structure, leading to impaired myosin filament assembly and function. These structural changes disrupt the normal contractile function of muscle cells, leading to the accumulation of myosin and other proteins within the muscle fibers. This protein aggregation causes cellular stress and impairs the function of organelles such as the sarcoplasmic reticulum and mitochondria. The dysfunction at the cellular level can trigger a cascade of events, including altered calcium homeostasis and energy metabolism, which further compromises muscle function. Neighboring cells and tissues are affected as the muscle fibers degenerate, leading to fibrosis and muscle weakness. The immune system may respond to the damaged muscle tissue, causing inflammation that can exacerbate muscle damage. Neuroinflammation is not typically a primary feature, but immune responses can contribute to the progression of muscle degeneration. White matter structures are generally not affected, as the condition primarily impacts muscle tissue. Symptoms often appear in a pattern that reflects the involvement of specific muscle groups, such as proximal limb muscles, due to the distribution of affected fibers. The variability in disease severity among patients can be attributed to the specific nature of the MYH7 mutation, genetic background, and environmental factors. Some patients may experience a more severe phenotype if the mutation significantly disrupts myosin function or if there are additional modifying genetic factors. Understanding the precise molecular mechanisms and pathways affected by MYH7 mutations continues to be an area of active research.
How is Autosomal dominant myosin storage myopathy Diagnosed?
Typical age of diagnosis: Diagnosis typically occurs in late adolescence to early adulthood when patients present with muscle weakness and exercise intolerance. A detailed family history often reveals an autosomal dominant pattern of inheritance.
Clinicians look for signs of muscle weakness, particularly in the proximal muscles, and assess for exercise intolerance. A family history of similar symptoms or known genetic conditions is crucial. Physical examination may reveal muscle atrophy or hypertrophy, and decreased muscle strength. This step helps to differentiate myopathy from other neuromuscular disorders and directs further testing.
Magnetic Resonance Imaging (MRI) is the preferred modality to assess muscle tissue. It reveals characteristic patterns of muscle involvement and fatty replacement. These findings support the diagnosis of myopathy and help exclude other conditions like inflammatory myopathies. MRI findings guide the selection of muscles for biopsy if needed.
Serum creatine kinase (CK) levels are measured to assess muscle damage. Elevated CK levels indicate muscle breakdown, supporting a myopathic process. Abnormal results prompt further investigation into specific muscle proteins and enzymes. These tests help refine the differential diagnosis and guide genetic testing.
The MYH7 gene is sequenced to identify pathogenic mutations. Missense mutations are commonly found in autosomal dominant myosin storage myopathy. Positive results confirm the diagnosis and provide a basis for genetic counseling. This information is crucial for family planning and assessing the risk in relatives.
Autosomal dominant myosin storage myopathy Treatment Options
Corticosteroids are used to reduce inflammation and slow muscle degeneration. They work by modulating the immune response and stabilizing muscle cell membranes. Prednisone is a commonly used corticosteroid in this context. Clinical studies show variable efficacy, with some patients experiencing improved muscle strength. Long-term use is limited by side effects such as osteoporosis and weight gain.
Physical therapy focuses on specific muscle strengthening and stretching techniques. The goal is to maintain muscle function and prevent contractures. Sessions are typically held 2-3 times a week, lasting 30-60 minutes each. Progress is measured by improvements in muscle strength and range of motion. Long-term benefits include enhanced mobility and reduced risk of falls.
Surgery is indicated for severe contractures that impair function. The procedure involves releasing tight tendons to improve joint mobility. Expected benefits include increased range of motion and improved quality of life. Surgical risks include infection and recurrence of contractures. Post-operative care involves intensive physical therapy to maintain surgical gains.
The care team includes neurologists, physiotherapists, occupational therapists, and social workers. Interventions focus on optimizing daily function and providing assistive devices. Psychosocial support includes counseling and support groups for patients and families. Education is provided on disease management and coping strategies. Long-term monitoring involves regular follow-ups to adjust care plans as needed.
When to See a Doctor for Autosomal dominant myosin storage myopathy
- Severe muscle weakness — this can indicate rapid disease progression and requires immediate medical attention.
- Sudden cardiac symptoms such as chest pain or palpitations — these may signal heart involvement and need urgent evaluation.
- Difficulty breathing — this could be a sign of respiratory muscle weakness and necessitates emergency care.
- Progressive muscle weakness — this suggests worsening of the condition and should prompt a consultation with a specialist.
- New onset of fatigue — this could indicate disease progression and warrants further investigation.
- Muscle cramps or pain — these symptoms may affect quality of life and should be discussed with a healthcare provider.
- Mild muscle stiffness — monitor for any increase in severity and maintain regular check-ups.
- Occasional muscle twitching — observe for frequency and report any significant changes to your doctor.
Autosomal dominant myosin storage myopathy — Frequently Asked Questions
Is this condition hereditary?
Autosomal dominant myosin storage myopathy is inherited in an autosomal dominant pattern, meaning one copy of the altered gene in each cell is sufficient to cause the disorder. There is a 50% chance of passing the condition to offspring. De novo mutations, which are new mutations not inherited from a parent, can occur but are less common. Individuals with a family history should consider genetic counseling to understand their risks. Genetic counseling is recommended to discuss family planning and management options.
What is the life expectancy for someone with this condition?
Life expectancy can vary depending on the age of onset and severity of symptoms. Early onset is generally associated with a more severe prognosis. Complications such as cardiac involvement can significantly impact mortality. Treatment and management strategies can improve quality of life and potentially extend survival. Realistic expectations should include ongoing monitoring and adaptation to changing symptoms.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis typically involves a combination of clinical evaluation, family history, and genetic testing. The time from first symptoms to diagnosis can vary but often takes several months to years. Neurologists and geneticists are commonly consulted during the diagnostic process. Delayed diagnosis may occur due to the rarity of the condition and overlapping symptoms with other disorders. Genetic testing confirming a mutation in the MYH7 gene usually finalizes the diagnosis.
Are there any new treatments or clinical trials available?
Research is ongoing, with promising developments in gene therapy and other novel approaches. Clinical trials can be found on ClinicalTrials.gov by searching for myosin storage myopathy or related terms. Patients should discuss potential trial participation with their healthcare provider. It's important to ask about the risks, benefits, and eligibility criteria for any trial. New treatments may become available in the next few years, but timelines can vary.
How does this condition affect daily life and activities?
The condition can significantly impact mobility and self-care, requiring adaptations in daily routines. Educational and occupational activities may need to be adjusted to accommodate physical limitations. Social and emotional challenges are common, and support from family and community resources is crucial. The family may experience increased caregiving responsibilities and emotional stress. Supports such as physical therapy, assistive devices, and counseling can greatly enhance quality of life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.A Review of Muscular Dystrophies.
Hoang T, Dowdy RAE · Anesth Prog · 2024 · PMID: 39503119
- 2.A novel heterozygous missense MYH7 mutation potentially causes an autosomal dominant form of myosin storage myopathy with dilated cardiomyopathy.
Naderi N, Mohsen-Pour N, Nilipour Y et al. · BMC Cardiovasc Disord · 2023 · PMID: 37794383
- 3.Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.
Ganassi M, Zammit PS · Eur J Transl Myol · 2022 · PMID: 35302338
- 4.Emery-Dreifuss Muscular Dystrophy.
Adam MP, Bick S, Mirzaa GM et al. · Unknown Journal · 1993 · PMID: 20301609
- 5.Emery-Dreifuss muscular dystrophy.
Puckelwartz M, McNally EM · Handb Clin Neurol · 2011 · PMID: 21496632
- 6.Limb-girdle muscular dystrophy.
Mathews KD, Moore SA · Curr Neurol Neurosci Rep · 2003 · PMID: 12507416
- 7.Emery-Dreifuss syndrome.
Emery AE · J Med Genet · 1989 · PMID: 2685312
- 8.Invertebrate models of lamin diseases.
Rzepecki R, Gruenbaum Y · Nucleus · 2018 · PMID: 29557730
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-14